Response to Comments: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer

This document contains only administrative metadata (comment and notice periods) and a title revision for LCD L39042; it does not contain any clinical coverage criteria, indications, limitations, documentation requirements, or frequency limits. To extract actionable coverage criteria, the full MolDX LCD L39042 text must be reviewed.